Friday, February 2, 2018
The second Exeltis Day scientific conferences are being held today and tomorrow in Valencia, bringing together over 300 gynaecologists to examine the latest developments in gynaecology
This will also be the stage where the preliminary findings of the FLEXO study will be presented, assessing the impact of information about contraception
New technologies and social media in gynaecology will be some of the current issues discussed during these days
Valencia, 2 February 2018_ Over 300 gynaecologists are gathering in Valencia this weekend to examine treatments and scientific findings in Woman's Healthcare at the second Exeltis Day scientific conferences, organised by the company Exeltis under the auspices of the European University of Madrid's Exeltis Chair on Women's Health.
Nutritional needs during pregnancy, angiogenic markers in pre-eclampsia, endometrial cancer, male fertility, urinary tract infections, HPV-related diseases and Women's Healthcare at all stages of life are some of the topics that will be discussed in this latest edition of Exeltis Day.
Over 30 renowned Spanish and international experts from will be examining the latest developments in this and other aspects of Women's Healthcare. According to Doctor Ezequiel Pérez Campos, the Chairman of “Exeltis Day 2018” and Head of the Obstetrics and Gynaecology Department of Requena Hospital in Valencia: “ despite being in its infancy, this scientific event is already generating a lot of interest among specialists in Obstetrics and Gynaecology, due to its varied and up-to-date programme”.
New technologies and social media are also currently having an impact on health, gynaecology and obstetrics, so this will be one of the new issues that will also be analysed by the attending specialists.
Preliminary findings of the FLEXO study:
Two significant developments in the field of contraception will be presented. Doctor Iñaki Lete, Department Head of the Obstetrics and Gynaecology Clinical Management Unit at Áraba University Hospital and Professor of Gynaecology and Obstetrics and the University of the Basque Country, will be presenting the first flexible continuous regimen marketed in Spain and the initial findings of the Flexo study, a cross-sectional study assessing the impact of information about oral contraceptives in a flexible regimen on the choices of women who seek contraceptive advice.
The company has conducted this research work together with the Spanish Contraception Association, this year achieving a high level of participation with over 1,300 women surveyed and over a hundred professionals.
Doctor Lete stresses the importance of a study like this. “We know that the decision to use a specific method of contraception lies with the woman. When they come to our surgeries and say that they want to take the pill, sometimes the doctors do not take the time to explain to them that there are different types. The aim of the study was to determine the impact of information about a new contraceptive and the flexible regimen on a woman's final decision and to analyse the factors that influence this decision”.
About Exeltis: Women's Health Unit: The aim of the Women's Health Unit is to support women in every stage of their lives, from fertility, pregnancy, childbirth and contraception to the menopause and, with the advice of specialists, to offer a wide range of treatments that meet the patient's needs and requirements in terms of reproductive health and its associated diseases.
Exeltis is part of the Insud Pharma group, a pharmaceutical company with over 40 years of experience and 15 manufacturing plants, 10 research centres and nearly 6,000 professionals, 4,000 of whom work in Exeltis.
“Exeltis is an organisation with a clear focus on innovation, excellence and healthcare, borne out of the natural development and sustained growth of Insud Pharma's pharmaceutical business”, says Alberto Fábregas, General Manager of Exeltis in Spain and Portugal.
In terms of Exeltis' research activity, this is conducted by harnessing the potential of the Group, the resources of its affiliates around the world, and its corporate research centre that specialises in the research and development of new products, from the initial phase to approval: “We believe that knowledge is a key factor for growth and fulfilling our commitment to the health and well-being of people”, remarks Fábregas.
A commitment to training and research into Women's Health
Exeltis has made a commitment to training by signing an agreement with the European University to create the ‘Exeltis Chair on Women's Health’, whose aim is to establish and conduct research activities in the area of Women's Health, e.g. organising these update conferences on gynaecology.
This agreement will also provide support to students who are studying for a PhD in similar fields to that of the Chair and will enable joint training activities to be held.
The programme of activities will focus on three lines of work: R&D+i, through the creation of grants for research into women's health with various scientific societies of gynaecology; the generation and dissemination of knowledge relating to the Chair; and holding training courses on women's health for gynaecologists and pharmacists.